MTF acquires PRP & PRFM technologies from Cascade Medical Enterprises
WAYNE, N.J., Jan. 6, 2012 /PRNewswire/ — Cascade Medical Enterprises, LLC (CME), a leading company with proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) technology for use in orthopedic therapeutic applications in soft tissue and bone repair, announced the sale of their technology to Musculoskeletal Transplant Foundation (MTF) and distribution by ConMed Linvatec for the worldwide orthopedic, dental, and wound care markets.
CME has had a long collaborative US distribution relationship with MTF for the sale of their products in the sports medicine market. This collaboration has enabled the companies to achieve a formative market presence establishing CME as a science-based provider of a unique technology for the collection, preparation, and delivery of an autologous blood-derived platelet and fibrin biologic. The CME technology has been developed into procedure specific systems and kits, marketed as the CASCADE® System. The key proprietary aspects of the CASCADE® technology are the ability to produce liquid, gel, and membrane formats for the PRP and PRFM to meet the needs of the specific procedure technique requirements.
The CASCADE® System is an FDA 510(k) cleared device that is designed to be used for the safe and rapid preparation of autologous PRP from a small sample of blood at the patient point of care. The PRP can be mixed with autograft and allograft bone prior to the application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
Autologous PRP and PRFM are biologic preparations that are derived from the patient’s own blood. Platelets are known to contain growth factors that stimulate the body’s natural healing of soft tissue and bone. The collection and concentration of these factors from a small sample of blood using systems that are safe, easy to use, and designed to maximize performance are unique to the CASCADE® technology. In addition to the platelets, the CASCADE® System collects and prepares a fibrin matrix that acts as a scaffold to enable cell migration into the repair site. Numerous scientific and clinical papers have been published.
See MTF’s web site: www.platelettherapy.com for more information
Tony Dimun, Chairman of CME said “We are pleased that our collaboration with MTF has led to this exciting opportunity to expand the reach of our technology with the sale of our technology to MTF and distribution by ConMed Linvatec on a worldwide basis. We are proud of our accomplishments in partnership with MTF in bringing this exciting autologous technology to the worldwide market.”
Nicholas Grippi, President and founder of CME, said “Our long relationship with MTF in building science-based support for our technology has established CME’s recognition as the leading edge of autologous biologics therapy.”
Frank DeBernardis, CEO of CME, said “The MTF Sports Medicine Marketing and Sales organization did an excellent job of pioneering the markets for autologous biologics. We are pleased to continue our support for MTF and ConMed Linvatec in the ongoing product development of this exciting technology. Additionally, this relationship will enable CME to focus on our emerging Aesthetic Factors® and Vertical Spine™ business ventures.”
“MTF has been pleased to work with CME over the past several years promoting their unique PRP technology. With this acquisition, we will now have the opportunity to greatly expand the promotion of CASCADE® PRP through our new partnership with ConMed Linvatec for the worldwide orthopedic, dental, and wound care markets,” said Bruce Stroever, President and CEO of MTF.
SOURCE Cascade Medical Enterprises, LLC